Complete remission induction with combined VBMCP chemotherapy and interferon (rIFNα2b) in patients with multiple myeloma

Leukemia and Lymphoma

Volumn 20, Issue 42130, 1996, Pages 447-452

  Oken, Martin M ^a   Kyle, Robert A ^b   Greipp, Philip R ^b   Kay, Neil E ^c   Tsiatis, Anastasios ^a,d   Gregory, Stephanie A ^e   Spiegel, Robert J ^f   O'connell, Michael J ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

chemotherapy; complete remission; induction; interferon alpha; myeloma; VBMCP

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; M PROTEIN; MELPHALAN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON ALFA-2B; LIFE TABLES; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYOCARDIAL INFARCTION; NEUTROPENIA; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINCRISTINE;

EID: 0029983414     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199609052427     Document Type: Article

References (28)

1. Oken M. M. Multiple Myeloma. Med. Clin, N. Am. 1984; 68: 757 – 787
2. Oken M. M., Tsiatis A., Abramson N., Click J. Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma. Proc ASCO 1984; 3: 270
3. Alexanian R., Gutterman J., Levy H. Interferon treatment for multiple myeloma. Clin. Haematol. 1982; 2: 211 – 220
4. Case D. C., Sonneborn H. L., Paul S. D., Hiebel J., Boyd M. A., Shipp M. A. Phase II Study of rDNA Alpha-2 Interferon (INTRON A) in Patients With Multiple Myeloma Utilizing an Escalating Induction Phase. Cancer Treat Rep. 1986; 7: 1986
5. Cooper M. R. Interferons in the treatment of multiple myeloma. Semin. Oncol. 1986; 1: 13 – 20, suppl 2
6. Gutterman J. U., Blumenschein G. R., Alexanian R. Leukocyte interferon-induced tumor regression in human metastatic breast cancer. multiple myeloma and malignant lymphoma. Ann. Int. Med. 1980; 9: 399 – 406
7. Ludwig H., Cortelezzi A., Van Camp B. G. K., Polli E., Scheithauer W., Kuzmits R. Treatment with Recombinant Interferon-Alpha-2C: Multiple Myeloma and Thrombocythaemia in Myeloproliferative Diseases. Oncology 1985; 4: 19 – 25, suppl 1
8. Mellstedt H., Aahre A., Bjorkholm M., Johansson B., Strander H., Brenning G. Interferon Therapy of Patients with Myeloma. Immunotherapy of Human Cancer, W Terry, S. Rosenberg. Elsevier North Holland. Inc., New York 1982; 387 – 391
9. Costanzi J. J., Pollard R. B. The Use of Interferon in the Treatment of Multiple Myeloma. Semin. Oncol. 1987; 14: 24 – 28, suppl 2
10. Ohno R. Interferons in the Treatment of Multiple Myeloma. Int. J. Cancer 1987; 1: 16 – 201
11. Oken M. M., Kyle R. A., Kay N. E., Greipp P. R., O'Connell M. J. Interferon in the treatment of refractory multiple myeloma: An Eastern Cooperative Oncology Group (ECOG) study. Leuk and Lymphoma. 1990; 1: 95 – 100
12. Quesada J. R., Alexanian R., Hawkins M., Barlogie B., Borden E., Itri L. Treatment of Multiple Myeloma With Recombinant Alpha Interferon. Blood 1986; 6: 275 – 278
13. Takaku F. Phase II study of interferon alfa-2 (Sch 30500) for hematopoietic tumors. Rinsyo iyaku. 1985; 1: 59 – 68
14. Wagstaff J., Loynds P., Scarffe J. H. Phase II study of rDNA human alpha-2 interferon in multiple myeloma. Cuncer Treat Rep. 1985; 6: 495 – 498
15. Oken M. M., Kyle R. A., Greipp P. R., Kay N. E., Tsiatis A., O'Connell M. J. Alternating cycles of VBMCP with interferon (rIFN-alpha 2) in the treatment of multiple myeloma. Proc. Am. Soc. Clin. Oncol. 1988; 7: 868A
16. Oken M. M., Kyle R. A. Strategies for combining in-terferon with chemotherapy for the treatment of multiple myeloma. Semin. Oncol. 1991; 1: 30 – 32, suppl 7
17. Duc J., Morel B., Peitrequin R., Frei P. C. Identification of monoclonal gammopathies: A comparison of immunofixation, immunoelectrophoresis and measurements of kappa- and lambda-immunoglobulin levels, J. Clin. Lab. Immunol. 1988; 2: 141 – 146
18. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649 – 655
19. Bergsagel D. E. Plasma Cell Myeloma. Hematology, W. J. Williams, E. Beutler, A. J. Erslev, M. A. Lichtman. McGraw Hill, New York 1990; 1114 – 1141
20. Billadeau D., Blackstadt M., Greipp P., Kyle R. A., Oken M. M., Kay N., Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease. Blood 1991; 7: 3021 – 3029
21. Costanzi J. J., Cooper M. R., Scarffe J. H., Ozer H., Grubbs S. S., Ferraresi R. W. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J. Clin. Oncol. 1991; 3: 654 – 659
22. Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V. M. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl, J. Med. 1990; 3: 1430 – 1434
23. Salmon S. E., Beckord J., Pugh R. P., Barlogie B., Crowley J. Alpha-interferon for remission maintenance: Preliminary report on the Southwest Oncology Group Study. Semin. Oncol. 1991; 1: 33 – 36, suppl 7
24. Salmon S. E., Crowley J. J., Grogan T. M., Finley P., Pugh R. P., Barlogie B. Combination chemotherapy, glucocorti-coids and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group Study. J. Clin. Oncof. 1994; 1: 2405 – 2414
25. Browman G. P., Rubin S., Walker I., Sickeri D., Belch A., O'Reilly S. Interferon α-2b maintenance therapy prolongs progression- free and overall survival in plasma cell myeloma: Results of a randomized tnal. Prnc. Am. Soc. Gin. Oncol. 1994; 13: 409, abst. 1391
26. Powles R., Cunningham D., Malpas J. S., Raje N., Milan S., Singhal S., Mehta J., Viner C., Treleavan J., Raymond J. A randomised trial of maintenance therapy with intron-A following high-dose melphalan and ABMT in myeloma. Bbod. 1994; 8: 535a, abst. 2127 (suppl 1)
27. Cooper M. R., Dear K., McIntyre O. R., Ozer H., Ellerton J., Canellos G. A randomized clinical trial comparing melphaladprednisone with or without interferon alpha-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study, J. Clin. Oncol. 1993; 1: 155 – 160
28. Osterborg A., Bjorkholm M., Bjoreman M., Brenning C., Carlson K., Celsing F. Natural interferon-a in combination with melphalan/prednisone versus melphalanlprednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood 1993; 8: 1428 – 1434